These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33390349)

  • 41. Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma.
    Knop S; Langer C; Engelhardt M; Mügge LO; Reichle A; Rösler W; Bassermann F; Hertenstein B; Kunitz A; Röllig C; Ostermann H; Schäfer-Eckart K; Ringhoffer M; Günther A; Junghanss C; Biersack H; Schreder M; Liebert A; Held S; Einsele H; Bargou RC
    Leukemia; 2017 Aug; 31(8):1816-1819. PubMed ID: 28439106
    [No Abstract]   [Full Text] [Related]  

  • 42. [HIV infection and porphyria cutanea tarda, report of a case].
    Gómez-Polo JC; Álvarez-Carretero M; Megía-Sánchez M; de Los Ángeles Lozano Parras M
    Med Clin (Barc); 2016 May; 146(9):e49-50. PubMed ID: 26723942
    [No Abstract]   [Full Text] [Related]  

  • 43. Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.
    Kumar S
    Curr Hematol Malig Rep; 2011 Jun; 6(2):104-12. PubMed ID: 21394431
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency.
    Ballester OF; Tummala R; Janssen WE; Fields KK; Hiemenz JW; Goldstein SC; Perkins JB; Sullivan DM; Rosen R; Sackstein R; Zorsky P; Saez R; Elfenbein GJ
    Bone Marrow Transplant; 1997 Oct; 20(8):653-6. PubMed ID: 9383228
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual porphyria of coexisting variegata and cutanea tarda.
    Sieg I; Bhutani LK; Doss MO
    Eur J Clin Chem Clin Biochem; 1995 Jul; 33(7):405-10. PubMed ID: 7548446
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma.
    Tang S; Lu Y; Zhang P; Chen D; Liu X; Du X; Cao J; Ye P; Chen L; Li S; Sha K; Zhuang XX; Xie Y; Wu X; Pei R
    Leuk Res; 2021 Nov; 110():106710. PubMed ID: 34619433
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Symptomatic porphyria cutanea tarda and B-immunoblastic lymphoma: is there an association?
    Younossi ZM; Pockros PJ
    Am J Hematol; 1996 Mar; 51(3):252-3. PubMed ID: 8619418
    [No Abstract]   [Full Text] [Related]  

  • 48. Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone.
    Arcani R; Venton G; Colle J; Suchon P; Ivanov V; Mercier C; Farnault L; Roche P; Lafage M; Brunet C; Azouza W; Pourroy B; Fanciullino R; Costello R
    Eur J Haematol; 2019 Oct; 103(4):385-392. PubMed ID: 31319001
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
    Tosi P; Zamagni E; Tacchetti P; Ceccolini M; Perrone G; Brioli A; Pallotti MC; Pantani L; Petrucci A; Baccarani M; Cavo M
    Biol Blood Marrow Transplant; 2010 Aug; 16(8):1115-21. PubMed ID: 20197100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Porphyria cutanea tarda and HIV/AIDS: a review of pathogenesis, clinical manifestations and management.
    Mansourati FF; Stone VE; Mayer KH
    Int J STD AIDS; 1999 Jan; 10(1):51-6. PubMed ID: 10215132
    [No Abstract]   [Full Text] [Related]  

  • 52. Generalized morphoea secondary to porphyria cutanea tarda.
    Stevens HP; Ostlere LS; Black CM; Rustin MH
    Br J Dermatol; 1993 Oct; 129(4):455-7. PubMed ID: 8105868
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advances in the treatment of multiple myeloma.
    Barlogie B; Jagannath S; Tricot G; Desikan KR; Fassas A; Siegel D
    Adv Intern Med; 1998; 43():279-320. PubMed ID: 9506186
    [No Abstract]   [Full Text] [Related]  

  • 54. Coexistence of subacute cutaneous lupus erythematosus and porphyria cutanea tarda: a case report.
    Camisa C; Fox M; Quillin A; Hibler JP
    Cutis; 1995 Aug; 56(2):101-3. PubMed ID: 8536489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tandem bone marrow transplantation in multiple myeloma.
    Musto P
    N Engl J Med; 2004 Apr; 350(14):1466-7; author reply 1466-7. PubMed ID: 15074004
    [No Abstract]   [Full Text] [Related]  

  • 56. Treatment of transplant-eligible patients with multiple myeloma in 2014.
    Landau H; Giralt S
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):815-27. PubMed ID: 25212884
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Porphyria cutanea tarda in a human immunodeficiency virus-positive patient.
    Grau-Echevarría A; Labrandero-Hoyos C; Peñuelas-Leal R; Blaya-Imbernón D; Finello M; Pérez-Pastor GM; Hernández-Bel P; Pérez-Ferriols A
    Med Clin (Barc); 2024 May; 162(10):e42. PubMed ID: 38151366
    [No Abstract]   [Full Text] [Related]  

  • 58. [Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
    de Alarcón Jiménez RM; Roca Meroño S; Alvarez Fernández GM; García Hernández MA; Navarro Parreño MJ; Jimeno Griñó C; Zarco Pedrinaci E; Molina Núñez M
    Nefrologia; 2011; 31(2):238-40. PubMed ID: 21461027
    [No Abstract]   [Full Text] [Related]  

  • 59. Porphyria cutanea tarda and spherocytosis: a non-random association?
    Du-Thanh A; Aguilar-Martinez P; Enescu C; Cunat S; Guillot B; Dereure O
    Acta Derm Venereol; 2013 May; 93(3):377-8. PubMed ID: 23093332
    [No Abstract]   [Full Text] [Related]  

  • 60. Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant.
    Jimenez-Zepeda VH; Duggan P; Neri P; Chaudhry A; Murray K; Culham M; Luider J; Fourie T; Rashid-Kolvear F; Bahlis NJ
    Leuk Lymphoma; 2016; 57(4):973-6. PubMed ID: 26450458
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.